RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a Phase 3 clinical trial evaluating calderasib (MK-1084), an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA QLEXâ"¢ (pembrolizumab and berahyaluronidase alfa-pmph) for the first-line treatment of patients with KRAS G12C-mutant, advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC). This randomi ...

RANCHO CUCAMONGA, CA / ACCESS Newswire / January 7, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the J.P. Morgan 2026 Healthcare Conference on Wednesday, January 14th, 2026, at 2:15 pm PT. ...

Core Viewpoint - The article highlights five top stocks to consider for investment in early 2026, emphasizing their strong earnings potential and growth opportunities in various sectors. Group 1: Amazon - Amazon is positioned as a strong investment due to its leadership in e-commerce and cloud computing, with a market cap of $2.6 trillion and a gross margin of 50.05% [5][3] - The company is leveraging artificial intelligence to enhance its e-commerce efficiency and AWS has an annual revenue run rate exceeding $132 billion [5][3] - The stock is considered a safe bet with a current price of $240.95, reflecting a 3.38% increase [4][3] Group 2: Eli Lilly - Eli Lilly is a leader in the weight loss drug market, particularly with its products tirzepatide (Zepbound and Mounjaro), contributing to significant sales growth [6][8] - The company has a market cap of $1 trillion and a gross margin of 83.03%, with a current stock price of $1,064.04, up 2.16% [7][6] - The weight loss drug market is projected to reach nearly $100 billion by the end of the decade, indicating substantial growth potential for Lilly [9] Group 3: Chewy - Chewy operates in the pet e-commerce space, expanding into veterinary services, which broadens its revenue opportunities [10][12] - The company has achieved profitability and 84% of its sales come from its Autoship service, providing predictable revenue [12][11] - Chewy's current market cap is $13 billion, with a gross margin of 28.58% and a stock price of $32.16, reflecting a slight increase of 0.05% [11][10] Group 4: Apple - Apple has underperformed compared to the S&P 500 but is now focusing on AI features, which may attract investors looking for growth [14][15] - The company has a market cap of $3.9 trillion and a gross margin of 46.91%, with a current stock price of $262.36, down 1.83% [15][14] - Apple's services segment is a significant growth area, consistently reporting record revenues [16] Group 5: Moderna - Moderna is identified as a recovery story, facing challenges due to declining vaccine sales but has a promising pipeline of late-stage candidates [18][19] - The company aims to expand its seasonal vaccine offerings from three to six products by 2028 and is working towards cash breakeven [19][20] - Moderna has a market cap of $14 billion, a gross margin of 38.93%, and a current stock price of $35.66, reflecting a 10.85% increase [19][18]

来源：环球网 "索托克拉在中国加速获批并实现全球首发，无疑是百济神州血液学产品管线进展的重要里程碑，标志 着我们的又一款自研药物将正式开始帮助患者，也进一步印证了百济神州在B细胞恶性肿瘤治疗领域的 引领性。"百济神州总裁、全球研发负责人汪来博士表示，"索托克拉在中国从受理至获批仅用时8个 月，此得益于索托克拉在研究中展现出深度且持久的缓解获益与良好的安全性，展示出其具备成为同类 最佳BCL2抑制剂的潜力，另外也反映出中国血液肿瘤患者出现耐药后的迫切治疗需求已被重视。我们 还在进一步探索索托克拉的潜力，以期帮助到全球更多患者。" 1月6日，百济神州宣布，旗下新一代BCL2抑制剂索托克拉片（百悦达®）获得国家药品监督管理局 （NMPA）附条件批准上市，用于治疗既往接受过至少包含布鲁顿酪氨酸激酶（BTK）抑制剂在内的一 种系统治疗的慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）成人患者，以及既往接受过至少 两种系统性治疗（含布鲁顿酪氨酸激酶[BTK]抑制剂）的复发或难治性套细胞淋巴瘤（MCL）成人患 者。此前，这两项适应症的上市申请已被NMPA药品审评中心（CDE）纳入优先审评程序。 据悉，索托克拉此次以 ...

Core Insights - GSK announced positive results from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, for bepirovirsen, an investigational antisense oligonucleotide for chronic hepatitis B treatment [1] Company Summary - Ionis Pharmaceuticals partnered with GSK for the development of bepirovirsen, which has shown promising safety and efficacy results in over 1,800 patients across 29 countries [1]

Core Insights - GSK's experimental drug for chronic hepatitis B infection has successfully met the main goals in two significant studies, indicating progress towards a potential functional cure for patients [1] Company Summary - GSK is advancing its research in chronic hepatitis B treatment with promising results from its experimental drug [1]

Biogen's collaboration with Eisai Co., Ltd. on Alzheimer's treatment "LEQEMBI" marks a significant stride in neurological disease management.The acceptance of the Biologics License Application for LEQEMBI in China could open new market opportunities for Biogen.Biogen's stock has seen a 15.1% increase in 2025, driven by successful product launches and a 29.9% increase in sales for Skyclarys.Biogen Inc. (NASDAQ:BIIB) is a leading biotechnology company with a focus on developing treatments for neurological dis ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

UBS set a price target of $25 for Pfizer (NYSE:PFE), indicating a slight overvaluation based on the current stock price of $25.43.Pfizer's stock has experienced a decline of 2.3% over the past month, underperforming against the Zacks S&P 500 composite and the Zacks Large Cap Pharmaceuticals industry.The company's market capitalization stands at approximately $144.59 billion, with a trading volume of 38,061,592 shares, highlighting significant investor interest.On January 6, 2026, UBS set a price target of $ ...

Group 1 - Envision Research, led by Lucas Ma, has over 20 years of investment experience and specializes in quantitative investment and renewable energy [1] - The firm offers two model portfolios: one focused on short-term survival and withdrawal, and the other on aggressive long-term growth [1] - Envision Early Retirement and Sensor Unlimited provide solutions for generating high income and growth with isolated risks through dynamic asset allocation [1] Group 2 - The firm provides direct access for clients to discuss investment ideas via chat, along with monthly updates on holdings and tax discussions [1] - Envision Research combines extensive experience in high-tech R&D, consulting, and portfolio management to inform its investment strategies [1]